Key result
Rivaroxaban initiation is linked to spontaneous vitreous hemorrhage, especially with concurrent baseline anticoagulation.
Why the study?
Rivaroxaban is increasingly prescribed for atrial fibrillation, but its association with spontaneous vitreous hemorrhage is not well described.
Case Report (n=3)
May warrant vigilance for vitreous hemorrhage with rivaroxaban plus dual anticoagulation; case series leaves open need for confirmatory studies.
IMPORTANCE: Rivaroxaban is an anticoagulant prescribed for the management of atrial fibrillation. We describe a correlation between rivaroxaban and spontaneous vitreous hemorrhage. OBSERVATIONS: Three patients developed spontaneous vitreous hemorrhage after initiating rivaroxaban anticoagulation. All 3 patients were taking an additional anticoagulant at the time of hemorrhage. CONCLUSIONS AND RELEVANCE: Rivaroxaban is increasingly prescribed as a replacement for warfarin sodium in the management of atrial fibrillation. Rivaroxaban anticoagulation may be associated with spontaneous vitreous hemorrhage. The risk of hemorrhage may be particularly elevated during the transition period when patients are switched from baseline anticoagulant to rivaroxaban therapy and are taking both anticoagulants simultaneously.
No takes yet. Share an insight, caveat, or question.
Jun et al. (2015) conducted a case report in Atrial fibrillation (n=3). Rivaroxaban was evaluated on Spontaneous vitreous hemorrhage. Rivaroxaban initiation may be associated with spontaneous vitreous hemorrhage, with the risk potentially elevated when patients are simultaneously taking an additional baseline anticoagulant.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: